Investigational New Drugs

, Volume 24, Issue 5, pp 455–456 | Cite as

Abraxane® induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency

  • J. Lee Villano
  • Divyesh Mehta
  • Latha Radhakrishnan
Case Report


Paclitaxel Metastatic Breast Cancer Febrile Neutropenia Taxol CYP2C8 Polymorphism 


  1. 1.
    Abraxis Oncology (2005) Abraxane (paclitaxel protein-bound particles for injectible suspension) prescribing information. Schaumburg, IL; JanuaryGoogle Scholar
  2. 2.
    Bristol-Myers Squibb Company (2005) Taxol (paclitaxel injection) prescribing information. Princeton, NJ; March 2003. Available from Taxol_PI.pdf. Accessed July 24, 2005
  3. 3.
    Abraxis Oncology: Abraxane: Phase III Clinical Data: Abraxane vs. Taxol in Metastatic Breast Cancer (Data on file)Google Scholar
  4. 4.
    van Schaik RH (2004) Implications of Cytochrome P450 Genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit 26:236–240PubMedCrossRefGoogle Scholar
  5. 5.
    Ibrahim NK, Desia N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremphor-free protein stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • J. Lee Villano
    • 1
  • Divyesh Mehta
    • 1
  • Latha Radhakrishnan
    • 2
  1. 1.Department of Medicine, Section of Hematology/Oncology and Cancer CenterUniversity of IllinoisChicago
  2. 2.College of PharmacyUniversity of IllinoisChicago

Personalised recommendations